ES2834402T3 - Terapia génica con RPGR para retinitis pigmentosa - Google Patents
Terapia génica con RPGR para retinitis pigmentosa Download PDFInfo
- Publication number
- ES2834402T3 ES2834402T3 ES15825383T ES15825383T ES2834402T3 ES 2834402 T3 ES2834402 T3 ES 2834402T3 ES 15825383 T ES15825383 T ES 15825383T ES 15825383 T ES15825383 T ES 15825383T ES 2834402 T3 ES2834402 T3 ES 2834402T3
- Authority
- ES
- Spain
- Prior art keywords
- rpgr
- human
- orf15
- viral vector
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 title claims abstract description 133
- 208000007014 Retinitis pigmentosa Diseases 0.000 title claims description 30
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 title abstract description 92
- 238000001415 gene therapy Methods 0.000 title description 10
- 102000050188 human RPGR Human genes 0.000 claims abstract description 42
- 239000002299 complementary DNA Substances 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 29
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 239000013603 viral vector Substances 0.000 claims description 24
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 claims description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 7
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims description 6
- 108091006109 GTPases Proteins 0.000 claims description 6
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 claims description 6
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 6
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 6
- 230000004777 loss-of-function mutation Effects 0.000 claims description 5
- 230000002123 temporal effect Effects 0.000 claims description 3
- 206010025421 Macule Diseases 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000000520 microinjection Methods 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 101000847476 Autographa californica nuclear polyhedrosis virus Uncharacterized 54.7 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 57
- 101000736075 Bacillus subtilis (strain 168) Uncharacterized protein YcbP Proteins 0.000 description 57
- 101001066788 Haemophilus phage HP1 (strain HP1c1) Probable portal protein Proteins 0.000 description 57
- 101000748192 Herpetosiphon aurantiacus Uncharacterized 15.4 kDa protein in HgiDIIM 5'region Proteins 0.000 description 57
- 230000035772 mutation Effects 0.000 description 38
- 210000001525 retina Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 28
- 239000013598 vector Substances 0.000 description 25
- 230000006870 function Effects 0.000 description 24
- 108091008695 photoreceptors Proteins 0.000 description 22
- 210000004081 cilia Anatomy 0.000 description 16
- 230000004044 response Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 230000002207 retinal effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 108010003730 Cone Opsins Proteins 0.000 description 6
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108090000799 Rhodopsin kinases Proteins 0.000 description 6
- 102100032198 Rootletin Human genes 0.000 description 6
- 101710175555 Rootletin Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002571 electroretinography Methods 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012014 optical coherence tomography Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 101000879212 Pseudomonas phage PAJU2 Structural protein 3 Proteins 0.000 description 4
- 102000004330 Rhodopsin Human genes 0.000 description 4
- 108090000820 Rhodopsin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001886 ciliary effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000000608 photoreceptor cell Anatomy 0.000 description 4
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000004960 subcellular localization Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100038211 Homo sapiens RPGR gene Proteins 0.000 description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 2
- 101100038212 Mus musculus Rpgr gene Proteins 0.000 description 2
- 101150059532 RPGR gene Proteins 0.000 description 2
- 208000036448 RPGR-related retinopathy Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 201000000467 X-linked cone-rod dystrophy 1 Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000006754 cone-rod dystrophy Diseases 0.000 description 2
- 229960000710 cyclopentolate hydrochloride Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000005304 optical glass Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 2
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000033810 Choroidal dystrophy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101000876012 Homo sapiens Conserved oligomeric Golgi complex subunit 4 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000005801 Rod Opsins Human genes 0.000 description 1
- 108010005063 Rod Opsins Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000019291 X-linked disease Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 201000000761 achromatopsia Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000000979 axoneme Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- RHKZVMUBMXGOLL-UHFFFAOYSA-N cyclopentolate hydrochloride Chemical compound Cl.C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 RHKZVMUBMXGOLL-UHFFFAOYSA-N 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000032575 lytic viral release Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000004281 retinal morphology Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028638P | 2014-07-24 | 2014-07-24 | |
| PCT/US2015/040866 WO2016014353A1 (en) | 2014-07-24 | 2015-07-17 | Rpgr gene therapy for retinitis pigmentosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2834402T3 true ES2834402T3 (es) | 2021-06-17 |
Family
ID=55163577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15825383T Active ES2834402T3 (es) | 2014-07-24 | 2015-07-17 | Terapia génica con RPGR para retinitis pigmentosa |
| ES20199208T Active ES2987090T3 (es) | 2014-07-24 | 2015-07-17 | Terapia génica con RPGR para retinitis pigmentosa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20199208T Active ES2987090T3 (es) | 2014-07-24 | 2015-07-17 | Terapia génica con RPGR para retinitis pigmentosa |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10314924B2 (enExample) |
| EP (2) | EP3191139B1 (enExample) |
| JP (3) | JP6654760B2 (enExample) |
| CN (1) | CN107206105A (enExample) |
| CA (1) | CA2991750C (enExample) |
| CY (1) | CY1123793T1 (enExample) |
| DK (2) | DK3821912T3 (enExample) |
| ES (2) | ES2834402T3 (enExample) |
| FI (1) | FI3821912T3 (enExample) |
| HR (2) | HRP20241154T1 (enExample) |
| HU (2) | HUE052781T2 (enExample) |
| LT (2) | LT3191139T (enExample) |
| PL (2) | PL3191139T3 (enExample) |
| PT (2) | PT3191139T (enExample) |
| RS (2) | RS61307B1 (enExample) |
| SI (2) | SI3191139T1 (enExample) |
| SM (2) | SMT202000715T1 (enExample) |
| WO (1) | WO2016014353A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3191139T (pt) * | 2014-07-24 | 2020-11-05 | Massachusetts Eye & Ear Infirmary | Terapia do gene rpgr para retinite pigmentosa |
| US20190054117A1 (en) * | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
| US10646588B2 (en) | 2015-03-11 | 2020-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | RP2 and RPGR vectors for treating X-linked retinitis pigmentosa |
| GB201516066D0 (en) | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
| GB201704192D0 (en) | 2017-03-16 | 2017-05-03 | Nightstarx Ltd | Treatment of Retinitis Pigmentosa |
| US11723988B2 (en) | 2017-10-20 | 2023-08-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector |
| WO2019099696A1 (en) * | 2017-11-15 | 2019-05-23 | The Regents Of The University Of Michigan | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
| JP2023517929A (ja) | 2020-03-11 | 2023-04-27 | マサチューセッツ アイ アンド イヤー インファーマリー | Ｎｍｎａｔ１関連網膜変性に対する遺伝子療法 |
| CN120350069A (zh) * | 2024-01-12 | 2025-07-22 | 北京中因科技有限公司 | 视网膜色素变性动物模型及其构建方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| JP3015383B2 (ja) | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
| DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| ATE163046T1 (de) | 1990-10-31 | 1998-02-15 | Somatix Therapy Corp | Genetische veränderung von endothelzellen |
| US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
| AU2044901A (en) | 1999-11-24 | 2001-06-04 | Cornell Research Foundation Inc. | Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests |
| GB0008801D0 (en) | 2000-04-10 | 2000-05-31 | Medical Res Council | Sequences |
| CN102925445A (zh) * | 2011-08-08 | 2013-02-13 | 刘军 | 一种获得rpgr 基因新的转录剪切形式的方法 |
| JP6199965B2 (ja) * | 2012-07-11 | 2017-09-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療 |
| GB201412011D0 (en) | 2014-07-04 | 2014-08-20 | Ucl Business Plc | Treatments |
| PT3191139T (pt) * | 2014-07-24 | 2020-11-05 | Massachusetts Eye & Ear Infirmary | Terapia do gene rpgr para retinite pigmentosa |
-
2015
- 2015-07-17 PT PT158253831T patent/PT3191139T/pt unknown
- 2015-07-17 CA CA2991750A patent/CA2991750C/en active Active
- 2015-07-17 HU HUE15825383A patent/HUE052781T2/hu unknown
- 2015-07-17 LT LTEP15825383.1T patent/LT3191139T/lt unknown
- 2015-07-17 PL PL15825383T patent/PL3191139T3/pl unknown
- 2015-07-17 HR HRP20241154TT patent/HRP20241154T1/hr unknown
- 2015-07-17 JP JP2017525514A patent/JP6654760B2/ja active Active
- 2015-07-17 SI SI201531413T patent/SI3191139T1/sl unknown
- 2015-07-17 HU HUE20199208A patent/HUE068183T2/hu unknown
- 2015-07-17 WO PCT/US2015/040866 patent/WO2016014353A1/en not_active Ceased
- 2015-07-17 FI FIEP20199208.8T patent/FI3821912T3/fi active
- 2015-07-17 ES ES15825383T patent/ES2834402T3/es active Active
- 2015-07-17 EP EP15825383.1A patent/EP3191139B1/en active Active
- 2015-07-17 RS RS20201416A patent/RS61307B1/sr unknown
- 2015-07-17 DK DK20199208.8T patent/DK3821912T3/da active
- 2015-07-17 ES ES20199208T patent/ES2987090T3/es active Active
- 2015-07-17 CN CN201580051512.3A patent/CN107206105A/zh active Pending
- 2015-07-17 US US15/328,617 patent/US10314924B2/en active Active
- 2015-07-17 EP EP20199208.8A patent/EP3821912B1/en active Active
- 2015-07-17 SM SM20200715T patent/SMT202000715T1/it unknown
- 2015-07-17 RS RS20240901A patent/RS65909B1/sr unknown
- 2015-07-17 DK DK15825383.1T patent/DK3191139T3/da active
- 2015-07-17 SI SI201532022T patent/SI3821912T1/sl unknown
- 2015-07-17 PT PT201992088T patent/PT3821912T/pt unknown
- 2015-07-17 PL PL20199208.8T patent/PL3821912T3/pl unknown
- 2015-07-17 SM SM20240309T patent/SMT202400309T1/it unknown
- 2015-07-17 LT LTEP20199208.8T patent/LT3821912T/lt unknown
- 2015-07-17 HR HRP20202023TT patent/HRP20202023T1/hr unknown
-
2019
- 2019-06-10 US US16/436,521 patent/US11045558B2/en active Active
- 2019-12-26 JP JP2019235539A patent/JP6966532B2/ja active Active
-
2021
- 2021-01-05 CY CY20211100002T patent/CY1123793T1/el unknown
- 2021-10-21 JP JP2021172128A patent/JP7198329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2834402T3 (es) | Terapia génica con RPGR para retinitis pigmentosa | |
| Pawlyk et al. | Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa | |
| Tolmachova et al. | Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo | |
| ES2826384T3 (es) | Terapia génica para trastornos oculares | |
| ES2716615T3 (es) | Métodos para expresar un polinucleótido de interés en la retina de un sujeto | |
| ES2946512T3 (es) | Terapia génica para el tratamiento de una enfermedad degenerativa de la retina | |
| IL254148B (en) | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones | |
| RS62359B1 (sr) | Lečenje amd upotrebom aav sflt-1 | |
| EP3959324B1 (en) | Aav vectors encoding mini-pcdh15 and uses thereof | |
| ES2983990T3 (es) | Vectores virales que comprenden regiones codificantes de RDH12 y métodos para tratar distrofias de la retina | |
| KR20190096329A (ko) | 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달 | |
| BR112020026606A2 (pt) | Métodos de tratamento de perda auditiva e/ou perda de visão associada à clrn1 | |
| HK40051900A (en) | Rpgr gene therapy for retinitis pigmentosa | |
| HK40051900B (en) | Rpgr gene therapy for retinitis pigmentosa | |
| US20240307559A1 (en) | Kcnv2 gene therapy | |
| Andres-Mateos et al. | Laterally spreading AAV. SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection. | |
| Mendoza et al. | songbird retina | |
| Schwartz | Improving AAV Retinal Gene Therapy for Batten Disease | |
| Matsuki | Development of gene therapy for achromatopsia due to CNGA3 mutations | |
| Duong | Use Of Induced Pluripotent Stem Cell Models To Elucidate Retinal Disease Pathogenesis And To Develop Gene-Based Therapies | |
| EA044520B1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
| Scalabrino | Adeno associated viral gene therapy targeting on bipolar cells restores function in a mouse model of congenital stationary night blindness |